NEUP
Neuphoria Therapeutics Inc.
Price Chart
Latest Quote
$4.36
-0.08 (-1.80%)
Current Price
| Previous Close | $4.44 |
| Open | $4.40 |
| Day High | $4.59 |
| Day Low | $4.28 |
| Volume | 75,340 |
Stock Information
| Shares Outstanding | 5.40M |
| Total Debt | $34K |
| Cash Equivalents | $19.44M |
| Revenue | $-13K |
| Net Income | $-17.43M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $23.56M |
| EPS (TTM) | $-7.90 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $4.16M |
| Sales | $-13K |
| Income | $-17.43M |
| Book/sh | $5.47 |
| Cash/sh | $3.60 |
| Employees | 7 |
Financial Ratios
| Quick Ratio | 13.91 |
| Current Ratio | 14.31 |
| Debt/Eq | 0.12 |
Returns & Margins
| ROA | -27.97% |
| ROE | -62.90% |
| Operating Margin | 110513.32% |
Ownership
| Insider Ownership | 7.70% |
| Institutional Ownership | 55.03% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.79 |
| P/S | -1776.12 |
| P/B | 0.80 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $4.72 |
| SMA50 | $4.90 |
| SMA200 | $6.03 |
| RSI | 33.74 |
| ATR | 0.3168 |
| Shares Float | 4.19M |
| Short Float | 0.68% |
| Short Ratio | 0.84 |
| Rel Volume | 1.15 |
Performance History
| Week | +1.63% |
| Month | -14.84% |
| Quarter | -5.42% |
| 6 Months | +12.08% |
| YTD | +14.14% |
| Year | -35.88% |
| 3 Years | -85.08% |
| 10 Years | -97.53% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $4.36 | 75,400 |
| 2026-06-22 | $4.44 | 48,900 |
| 2026-06-18 | $4.31 | 150,600 |
| 2026-06-17 | $4.31 | 15,500 |
| 2026-06-16 | $4.28 | 69,600 |
| 2026-06-15 | $4.29 | 107,000 |
| 2026-06-12 | $4.37 | 43,000 |
| 2026-06-11 | $4.49 | 80,800 |
| 2026-06-10 | $4.42 | 67,000 |
| 2026-06-09 | $4.66 | 52,700 |
| 2026-06-08 | $4.67 | 64,200 |
| 2026-06-05 | $4.49 | 82,600 |
| 2026-06-04 | $4.84 | 129,500 |
| 2026-06-03 | $4.70 | 76,500 |
| 2026-06-02 | $4.89 | 107,000 |
| 2026-06-01 | $5.30 | 38,200 |
| 2026-05-29 | $5.31 | 20,300 |
| 2026-05-28 | $5.36 | 47,100 |
| 2026-05-27 | $5.40 | 15,400 |
| 2026-05-26 | $5.46 | 23,800 |
About Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.
đ° Latest News
Here's Why We're Not At All Concerned With Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn Situation
Simply Wall St. âĸ 2026-02-19T11:00:16Z
Is Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Worth US$4.4 Based On Its Intrinsic Value?
Simply Wall St. âĸ 2025-10-31T10:51:05Z
BC-Most Active Stocks
Associated Press Finance âĸ 2025-10-24T14:30:17ZNeuphoria scraps social anxiety hopeful after Phase III miss
Clinical Trials Arena âĸ 2025-10-22T16:53:19Z
Investors Parse Earnings Reports With US Equity Futures Flat Tuesday Pre-Bell
MT Newswires âĸ 2025-10-21T12:09:51ZNeuphoria Says Phase 3 Trial of BNC210 to Treat Social Anxiety Disorder Did Not Meet Primary Endpoint
MT Newswires âĸ 2025-10-20T21:18:55Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | - | $0 | $0 | $181,356 |
| Operating Revenue | - | $0 | $0 | $181,356 |
| Expenses | ||||
| Total Expenses | - | $17,797,161 | $21,560,234 | $14,862,393 |
| Other Income Expense | - | $1,997,578 | $-283,775 | $-395,782 |
| Net Non Operating Interest Income Expense | - | $220,097 | $323,158 | $-23,593 |
| Operating Expense | - | $17,797,161 | $21,560,234 | $14,862,393 |
| Other Operating Expenses | - | $-95,215 | $-422,742 | $-1,413,483 |
| General And Administrative Expense | - | $8,474,591 | $8,911,271 | $5,270,015 |
| Interest Expense | - | - | $14,085 | $18,485 |
| Rent Expense Supplemental | - | - | $145,853 | $180,535 |
| Total Other Finance Cost | - | - | $5,264 | $11,896 |
| Interest Expense Non Operating | - | - | $14,085 | $18,485 |
| Other Non Operating Income Expenses | - | - | - | $4,591 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | - | $-15,492,166 | $-21,381,677 | $-14,968,465 |
| Net Interest Income | - | $220,097 | $323,158 | $-23,593 |
| Interest Income | - | $220,097 | $323,158 | $6,789 |
| Normalized Income | - | $-17,477,759 | $-21,099,605 | $-14,571,590 |
| Net Income From Continuing And Discontinued Operation | - | $-15,492,166 | $-21,381,677 | $-14,968,465 |
| Total Operating Income As Reported | - | $-17,892,376 | $-21,982,976 | - |
| Net Income Common Stockholders | - | $-15,492,166 | $-21,381,677 | $-14,968,465 |
| Net Income | - | $-15,492,166 | $-21,381,677 | $-14,968,465 |
| Net Income Including Noncontrolling Interests | - | $-15,492,166 | $-21,381,677 | $-14,968,465 |
| Net Income Continuous Operations | - | $-15,492,166 | $-21,381,677 | $-14,968,465 |
| Pretax Income | - | $-15,579,486 | $-21,520,851 | $-15,100,411 |
| Interest Income Non Operating | - | $220,097 | $323,158 | $6,789 |
| Operating Income | - | $-17,797,161 | $-21,560,234 | $-14,681,036 |
| Special Income Charges | - | - | $-654,107 | $-645,383 |
| Net Income Discontinuous Operations | - | - | - | $0 |
| Depreciation Amortization Depletion Income Statement | - | - | - | - |
| Depreciation And Amortization In Income Statement | - | - | - | - |
| Amortization Of Intangibles Income Statement | - | - | - | - |
| Depreciation Income Statement | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-0.23 | $-0.12 | $-0.16 | $-0.17 |
| Basic EPS | $-0.23 | $-0.12 | $-0.16 | $-0.17 |
| Other | ||||
| Diluted Average Shares | $1,622,924 | $149,800,544 | $122,394,618 | $1,353,350,744 |
| Basic Average Shares | $1,622,924 | $149,800,544 | $122,394,618 | $1,353,350,744 |
| Tax Effect Of Unusual Items | - | $11,985 | $-1,703 | $-3,498 |
| Tax Rate For Calcs | - | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | - | $-19,131,748 | $-20,613,267 | $-13,918,377 |
| Total Unusual Items | - | $1,997,578 | $-283,775 | $-400,374 |
| Total Unusual Items Excluding Goodwill | - | $1,997,578 | $-283,775 | $-400,374 |
| Reconciled Depreciation | - | $662,991 | $663,192 | $763,175 |
| EBITDA (Bullshit earnings) | - | $-17,134,170 | $-20,897,042 | $-14,318,751 |
| EBIT | - | $-17,797,161 | $-21,560,234 | $-15,081,926 |
| Diluted NI Availto Com Stockholders | - | $-15,492,166 | $-21,381,677 | $-14,968,465 |
| Tax Provision | - | $-87,320 | $-139,174 | $-131,947 |
| Gain On Sale Of Security | - | $1,997,578 | $-283,775 | $245,010 |
| Research And Development | - | $9,417,785 | $13,071,705 | $11,005,860 |
| Selling General And Administration | - | $8,474,591 | $8,911,271 | $5,270,015 |
| Other Gand A | - | $8,474,591 | $8,911,271 | $5,089,480 |
| Gain On Sale Of Ppe | - | - | $0 | $-1,257 |
| Restructuring And Mergern Acquisition | - | - | $654,107 | $644,127 |
| Rent And Landing Fees | - | - | $145,853 | $180,535 |
| Amortization | - | - | - | - |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $3,332,832 | $7,186,124 | $23,530,941 | $18,972,049 |
| Total Assets | $27,649,093 | $28,562,948 | $44,927,475 | $40,770,155 |
| Total Non Current Assets | $14,455,335 | $15,236,336 | $16,165,818 | $17,533,540 |
| Other Non Current Assets | $78,826 | $78,897 | $81,861 | $89,409 |
| Goodwill And Other Intangible Assets | $14,157,540 | $14,824,439 | $15,619,941 | $16,789,759 |
| Other Intangible Assets | $5,467,522 | $6,130,253 | $6,767,840 | $7,472,618 |
| Current Assets | $13,193,758 | $13,326,612 | $28,761,657 | $23,236,614 |
| Prepaid Assets | $458,765 | $797,478 | $1,005,089 | $646,746 |
| Receivables | $126,884 | $426,087 | $4,666,991 | $849,854 |
| Other Receivables | $96,154 | $416,072 | $4,651,941 | $844,349 |
| Taxes Receivable | $30,444 | $9,758 | $15,049 | $5,505 |
| Accrued Interest Receivable | $286 | $257 | - | - |
| Cash Cash Equivalents And Short Term Investments | $12,608,109 | $12,103,047 | $23,089,577 | $21,412,701 |
| Cash And Cash Equivalents | $12,608,109 | $12,103,047 | $23,089,577 | $21,412,701 |
| Cash Financial | - | $18,250,255 | $23,089,577 | $21,412,701 |
| Restricted Cash | - | - | $0 | $327,313 |
| Non Current Prepaid Assets | - | - | - | $89,409 |
| Other Current Assets | - | - | - | $699,427 |
| Accounts Receivable | - | - | - | $144,771 |
| Gross Accounts Receivable | - | - | - | $144,771 |
| Debt | ||||
| Total Debt | $272,738 | $386,915 | $477,150 | $652,041 |
| Long Term Debt And Capital Lease Obligation | $117,628 | $239,835 | $367,057 | $521,145 |
| Current Debt And Capital Lease Obligation | $155,110 | $147,080 | $110,093 | $130,896 |
| Current Debt | $33,120 | $33,150 | - | - |
| Other Current Borrowings | $33,120 | $33,150 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $10,158,721 | $6,552,385 | $5,776,593 | $5,008,346 |
| Total Non Current Liabilities Net Minority Interest | $6,329,648 | $3,813,597 | $3,468,217 | $3,234,781 |
| Other Non Current Liabilities | $590,648 | $2,471,049 | $1,856,674 | $1,324,349 |
| Derivative Product Liabilities | $4,657,832 | $0 | - | - |
| Non Current Deferred Liabilities | $963,540 | $1,102,713 | $1,237,291 | $1,384,191 |
| Non Current Deferred Taxes Liabilities | $963,540 | $1,102,713 | $1,237,291 | $1,384,191 |
| Current Liabilities | $3,829,073 | $2,738,788 | $2,308,376 | $1,773,565 |
| Other Current Liabilities | $37,581 | $39,405 | - | - |
| Payables And Accrued Expenses | $3,636,382 | $2,552,303 | $1,916,708 | $1,363,219 |
| Payables | $2,243,662 | $1,439,291 | $1,070,993 | $772,934 |
| Accounts Payable | $2,243,662 | $1,439,291 | $1,070,993 | $772,934 |
| Other Payable | - | - | - | $590,285 |
| Equity | ||||
| Common Stock Equity | $17,490,372 | $22,010,563 | $39,150,882 | $35,761,809 |
| Total Equity Gross Minority Interest | $17,490,372 | $22,010,563 | $39,150,882 | $35,761,809 |
| Stockholders Equity | $17,490,372 | $22,010,563 | $39,150,882 | $35,761,809 |
| Gains Losses Not Affecting Retained Earnings | $-3,013,595 | $-3,058,783 | $8,615,100 | $8,601,228 |
| Other Equity Adjustments | $-3,013,595 | $-3,058,783 | - | $4,754,982 |
| Retained Earnings | $-177,977,071 | $-162,484,905 | $-119,219,156 | $-115,736,387 |
| Other | ||||
| Ordinary Shares Number | $198,711,663 | $1,468,735,424 | $1,353,350,744 | $1,007,596,744 |
| Share Issued | $198,711,663 | $1,468,735,424 | $1,353,350,744 | $1,007,596,744 |
| Tangible Book Value | $3,332,832 | $7,186,124 | $23,530,941 | $18,972,049 |
| Invested Capital | $17,523,492 | $22,043,713 | $39,150,882 | $35,761,809 |
| Working Capital | $9,364,685 | $10,587,824 | $26,453,281 | $21,463,049 |
| Capital Lease Obligations | $239,618 | $353,765 | $477,150 | $652,041 |
| Total Capitalization | $17,490,372 | $22,010,563 | $39,150,882 | $35,761,809 |
| Additional Paid In Capital | $198,481,027 | $187,554,251 | - | - |
| Capital Stock | $11 | $0 | $149,754,939 | $142,896,967 |
| Common Stock | $11 | $0 | $149,754,939 | $142,896,967 |
| Long Term Capital Lease Obligation | $117,628 | $239,835 | $367,057 | $521,145 |
| Current Capital Lease Obligation | $121,990 | $113,930 | $110,093 | $130,896 |
| Current Accrued Expenses | $1,392,720 | $1,113,012 | $845,715 | $590,285 |
| Goodwill | $8,690,018 | $8,694,186 | $8,852,101 | $9,317,142 |
| Net PPE | $218,969 | $333,000 | $464,015 | $654,372 |
| Accumulated Depreciation | $-45,722 | $-45,237 | $-173,357 | $-1,209,586 |
| Gross PPE | $218,969 | $378,237 | $637,372 | $1,863,958 |
| Other Properties | $218,969 | $330,478 | - | $1,783,750 |
| Machinery Furniture Equipment | $47,716 | $47,759 | $49,554 | $80,208 |
| Employee Benefits | - | $22,398 | $7,196 | $5,096 |
| Pensionand Other Post Retirement Benefit Plans Current | - | $457,017 | $281,575 | $279,449 |
| Leases | - | $854,500 | $587,819 | $1,783,750 |
| Properties | - | $0 | $0 | $0 |
| Foreign Currency Translation Adjustments | - | - | - | $3,846,246 |
| Non Current Pension And Other Postretirement Benefit Plans | - | - | - | $6,782 |
| Investments And Advances | - | - | - | $119,000 |
| Other Investments | - | - | - | $119,000 |
| Other Short Term Investments | - | - | - | $327,313 |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-14,680,777 | $-14,637,720 | $-14,966,864 | $-5,665,228 |
| Operating Activities | ||||
| Operating Cash Flow | $-14,680,777 | $-14,637,720 | $-14,965,802 | $-5,664,125 |
| Cash Flow From Continuing Operating Activities | $-14,680,777 | $-14,637,719 | $-14,965,802 | $-5,664,125 |
| Operating Gains Losses | $-366,333 | $-556,782 | $509,225 | $-786,452 |
| Cash Flowsfromusedin Operating Activities Direct | - | - | - | $-5,664,125 |
| Classesof Cash Receiptsfrom Operating Activities | - | - | - | $2,490,200 |
| Investing Activities | ||||
| Investing Cash Flow | - | $317,415 | $427,675 | $-60,262 |
| Cash Flow From Continuing Investing Activities | - | $317,415 | $427,675 | $-60,262 |
| Capital Expenditure | - | - | $-1,062 | $-1,103 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $10,111,979 | $3,858,451 | $22,625,656 | $32,935,724 |
| Financing Cash Flow | $15,108,794 | $3,858,451 | $18,570,540 | $23,707,479 |
| Cash Flow From Continuing Financing Activities | $15,108,794 | $3,858,451 | $18,570,540 | $23,707,479 |
| Net Common Stock Issuance | $10,111,979 | $3,858,451 | $22,625,656 | $32,935,724 |
| Common Stock Issuance | $10,111,979 | $3,858,451 | $22,625,656 | $32,935,724 |
| Net Other Financing Charges | - | $-1,126,827 | $-3,935,270 | $-312,165 |
| Repurchase Of Capital Stock | - | - | - | $-415,479 |
| Other | ||||
| End Cash Position | $12,686,935 | $12,181,944 | $23,089,577 | $21,412,701 |
| Beginning Cash Position | $12,181,944 | $23,205,035 | $19,605,036 | $3,439,432 |
| Effect Of Exchange Rate Changes | $76,974 | $-243,822 | $-547,872 | $-9,823 |
| Changes In Cash | $428,017 | $-10,779,269 | $4,032,413 | $17,983,092 |
| Proceeds From Stock Option Exercised | $4,996,815 | $0 | - | - |
| Change In Working Capital | $1,454,857 | $4,584,489 | $-3,853,644 | $1,227,117 |
| Change In Other Working Capital | $-139,173 | $-139,173 | $-103,700 | $-182,838 |
| Change In Other Current Liabilities | $-126,111 | $-99,767 | $0 | $0 |
| Change In Payables And Accrued Expense | $1,082,225 | $512,255 | $674,084 | $-47,563 |
| Change In Accrued Expense | $277,854 | $138,079 | - | - |
| Change In Payable | $804,371 | $374,176 | $674,084 | $-47,563 |
| Change In Account Payable | $804,371 | $374,176 | - | - |
| Change In Prepaid Assets | $338,713 | $173,975 | - | - |
| Change In Receivables | $299,203 | $4,137,199 | $-4,011,086 | $1,521,868 |
| Changes In Account Receivables | $299,203 | $4,137,199 | $-26,930 | $25,604 |
| Other Non Cash Items | $-1,754,934 | $707,749 | $637,338 | $-1,831,326 |
| Stock Based Compensation | $814,808 | $1,345,309 | $1,946,569 | $983,012 |
| Depreciation Amortization Depletion | $662,991 | $663,192 | $763,175 | $1,277,933 |
| Depreciation And Amortization | $662,991 | $663,192 | $763,175 | $1,277,933 |
| Gain Loss On Investment Securities | $-338,983 | - | - | - |
| Net Foreign Currency Exchange Gain Loss | $-27,350 | $-556,782 | $507,968 | $-802,237 |
| Net Income From Continuing Operations | $-15,492,166 | $-21,381,677 | $-14,968,465 | $-6,534,409 |
| Repayment Of Debt | - | $-105,936 | $-119,846 | $-8,916,080 |
| Net Issuance Payments Of Debt | - | $-105,936 | $-119,846 | $-8,916,080 |
| Net Long Term Debt Issuance | - | $-105,936 | $-119,846 | $-8,916,080 |
| Long Term Debt Payments | - | $-105,936 | $-119,846 | $-8,916,080 |
| Interest Received Cfi | - | $317,415 | $8,610 | $3,076 |
| Net Investment Purchase And Sale | - | $0 | $299,681 | $-89,008 |
| Sale Of Investment | - | $0 | $299,681 | $0 |
| Purchase Of Investment | - | $0 | $0 | $-89,008 |
| Net PPE Purchase And Sale | - | $0 | $119,385 | $25,670 |
| Sale Of PPE | - | $0 | $120,447 | $26,773 |
| Purchase Of PPE | - | $0 | $-1,062 | $-1,103 |
| Change In Other Current Assets | - | $170,945 | $-412,942 | $-64,351 |
| Net Business Purchase And Sale | - | - | $0 | $0 |
| Purchase Of Business | - | - | $0 | $0 |
| Change In Inventory | - | - | $0 | $0 |
| Gain Loss On Sale Of PPE | - | - | $0 | $0 |
| Interest Paid Supplemental Data | - | - | - | $726,420 |
| Common Stock Payments | - | - | - | $-415,479 |
| Interest Paid Direct | - | - | - | $-545,786 |
| Classesof Cash Payments | - | - | - | $-7,608,538 |
| Paymentsto Suppliersfor Goodsand Services | - | - | - | $-7,608,538 |
| Receiptsfrom Government Grants | - | - | - | $2,193,560 |
| Receiptsfrom Customers | - | - | - | $296,639 |
Fetched: 2026-06-16